Therapy Areas: Respiratory
Roche offers VENTANA PD-L1 Assay in counties accepting CE mark
12 September 2022 -

Switzerland-based Roche (SIX: RO, ROG) (OTCQX: RHHBY) announced on Friday that the VENTANA PD-L1 (SP263) Assay is offered in counties accepting the CE mark as a companion diagnostic to recognise non-small cell lung cancer (NSCLC) patients eligible for treatment with Libtayo (cemiplimab), a PD-1 inhibitor therapy produced by Regeneron.

The launch of the product is to result in more patients having access to an additional immunotherapy option with Libtayo.

Jill German, Head of Pathology Lab at Roche Diagnostics, said, 'With our companion diagnostics, we can help ensure each patient gets the most appropriate targeted treatment. This approval gives eligible advanced lung cancer patients access to the immunotherapy Libtayo as a first-line treatment. Our high medical value PD-L1 assay portfolio is continuing to help improve access to personalised medicine.'



Related Headlines